CHAIRMAN

Julian has over 25 years of experience in the biotechnology and medical technology sectors, as well as in investment banking. He has worked with both public and private companies, bringing a number of technologies through from discovery to market, as well as experience in capital raisings, company restructuring, licensing, business development and M&A transactions. He has a PhD from La Trobe University / Oxford University.

Julian is currently a non-executive director of LTR Pharma (ASX:LTP) and has held senior executive roles and directorships at several Australian and international life science companies, both listed and private, including Avexa Ltd (ASX:AVX), Opyl Ltd (ASX:OPL) and Admedus Ltd (ASX:AHZ).

NON-EXECUTIVE DIRECTOR

Doug is the former Managing Director and CEO of Nufarm Limited (ASX:NUF) and brings to the Board strong leadership skills and experience in agribusiness, marketing and innovation. He is Chairman of Rathbone Wine Group, Director of Cotton Seed Distributors, Leaf Resources (ASX:LER) and AgBiTech Pty Ltd, an Honorary Life Governor of the Royal Children's Hospital and a former Director of the CSIRO and the Burnett Centre for Medical Research. Over a 40-year career at Nufarm, Doug led the transformation of a small Australian agribusiness company into one of the world's leading crop protection and seed companies with an extensive global footprint.

MANAGING DIRECTOR & CHIEF EXECUTIVE OFFICER

Jenni has over 15 years of senior finance executive experience in the medical, biotechnology and technology sectors, within small-mid cap ASX-listed companies. In addition to financial management, investor relations & corporate governance experience, Jenni has successfully completed multiple capital raisings and M&A transactions including company acquisitions, asset sales, and a take-over defence. Most recently, Jenni was Chief Financial Officer & Company Secretary of communications company Whispir Ltd (ASX:WSP), and prior to that was CFO & Company Secretary of digital imaging company, Mach7 Technologies (ASX:M7T). She has previously held executive roles with biotechnology companies Alchemia Limited (ASX:ACL) and Mesoblast Limited (ASX:MSB). Jenni is a member of Chartered Accountants Australia & New Zealand, a Graduate of the Governance Institute of Australia, and has a Bachelor of Business Studies (majoring in accounting) from Massey University in New Zealand.

NON-EXECUTIVE DIRECTOR

Robert is an experienced senior executive who has delivered extensive leadership and operational outcomes across a wide variety of healthcare industries, including pharmaceutical, nutraceutical, infant formula, consumer, medical devices, and diagnostics. He has an applied science degree in Medical Science, a MBA, and is a Graduate of the Australian Institute of Company Directors. Having worked both globally and in Australia in leading commercial healthcare organisations, he brings substantial and diverse commercial and scientific understanding to the Company. Robert has held senior executive roles at several pharmaceutical and consumer healthcare entities including Aspen Pharmacare Australia Pty Ltd, Sanofi Australia, and Mayne Group. He has also served on the board of the peak OTC industry body being Consumer Healthcare Products Australia. Robert also has experience in the medicinal cannabis sector, being a former member of the advisory board to Leafcann Group Pty Ltd.

Robert is currently an advisor and consultant to the pharmaceutical industry.

JOINT COMPANY SECRETARY

Steven Notaro is the Joint Company Secretary and Head of Legal and Regulatory Affairs at Cann Group. He is a qualified lawyer, with a background in contract law, intellectual property, consumer law and corporate law.

Steven joined Cann Group in 2014, where he assisted in the early establishment of the business, including the listing of the Company on the ASX and the granting to Cann of the first medicinal cannabis licence issued in Australia under the Narcotic Drugs Act.

Steven manages the legal and regulatory affairs of the business.